Galleri and MCED Tests vs. Standard Screening: What Actually Reduces Cancer Mortality?

For decades, the holy grail of preventive medicine has been a single, simple blood test capable of detecting cancer before symptoms arise.

Recently, that concept entered the commercial market. Multi-cancer early detection (MCED) tests, most notably the Galleri test by GRAIL, have gained substantial traction in private clinics and concierge practices. These liquid biopsies analyze circulating blood to detect a shared methylation signal across dozens of cancer types from a single blood draw.

To a proactive patient, paying out-of-pocket for a test that screens for more than 50 cancers sounds like an obvious investment in long-term health.

However, in clinical oncology and preventive medicine, the adoption of MCED tests is approached with significant caution. While the genomic sequencing and machine learning behind liquid biopsies are technologically impressive, the real-world clinical performance of these tests in asymptomatic populations reveals major blind spots [1].

Here is an evidence-based breakdown of how the Galleri test works, what recent randomized trial data actually show, and why multi-cancer blood tests cannot replace guideline-endorsed cancer screenings.

1. How Liquid Biopsies Work: The Science of Cell-Free DNA

To evaluate the capabilities and limitations of MCED tests, it is essential to understand what they measure in the bloodstream:

• Cell-Free DNA (cfDNA): As cells throughout the body naturally die and regenerate, they shed tiny fragments of DNA into the circulation.

• Circulating Tumor DNA (ctDNA): Malignant cells also shed DNA into the bloodstream. However, in very early-stage disease, tumors shed relatively little DNA compared to the vast sea of normal cell-free DNA.

• Targeted Methylation Sequencing: Tests like Galleri analyze specific chemical modifications—known as methylation patterns—on this circulating DNA.

Using machine learning classifiers, the assay evaluates these methylation "barcodes" to determine whether an abnormal cancer signal is present and, if so, predicts the tissue of origin (such as the pancreas, colon, or lung) with roughly 85% to 90% accuracy in confirmed cases [1, 2].

2. The Stage-Sensitivity Gap: Why Stage I Detection Remains Elusive

The primary objective of any cancer screening test is early interception—catching tumors at Stage I or Stage II when they are localized and amenable to curative surgical resection.

This is where current multi-cancer blood tests face a fundamental biological limitation.

In clinical validation trials, the sensitivity of the Galleri test is heavily stage-dependent [1]:

• Stage I: Approximately 17% sensitivity

• Stage II: Approximately 40% sensitivity

• Stage III: Approximately 77% sensitivity

• Stage IV: Approximately 90% sensitivity

Because early-stage tumors shed minimal amounts of DNA into the bloodstream, the test misses more than 80% of Stage I cancers [1]. While overall early-stage sensitivity (Stages I and II combined) is higher, the test remains predominantly effective at identifying advanced, late-stage malignancies that are already shedding significant genomic material into circulation [1, 3].

3. What the Clinical Trials Show: The NHS-Galleri Trial

A common assumption among consumers is that catching a cancer signal on a blood test automatically leads to improved survival. In clinical epidemiology, this requires rigorous verification through randomized controlled trials (RCTs).

The largest evaluation to date—the NHS-Galleri trial in the United Kingdom, which enrolled more than 140,000 asymptomatic adults aged 50 to 77—recently completed its initial randomized phase [4].

The trial was designed to evaluate whether annual MCED screening could achieve a statistically significant reduction in the combined rate of late-stage (Stage III and IV) cancer diagnoses.

The trial did not meet its primary endpoint.

While investigators noted a reduction in Stage IV diagnoses for a prespecified subset of cancers, the overall reduction in late-stage diagnoses across the population was not statistically significant [4].

Furthermore, whether MCED screening ultimately reduces overall cancer mortality remains unproven. Definitive mortality-endpoint trials, such as the National Cancer Institute's Vanguard study, are currently underway to determine if multi-cancer blood testing actually saves lives or simply discovers advanced disease slightly earlier without changing the long-term clinical trajectory [4].

4. The Gold Standard: Proven Mortality Reduction

Why do preventive physicians continue to prioritize traditional anatomical screenings over a broad blood test?

Because guideline-endorsed screenings have decades of randomized controlled trial data demonstrating that they directly reduce disease-specific mortality [4]:

• Colonoscopy: Operates as both a detection tool and an active prevention procedure. It physically identifies and removes precancerous polyps (adenomas) before they can undergo malignant transformation. A blood test only turns positive after a tumor has already developed and begun shedding DNA.

• Low-Dose Chest CT: Demonstrably reduces lung cancer mortality in individuals with a significant smoking history by identifying early-stage, resectable nodules.

• Mammography, Cervical Cytology, and HPV Testing: Large-scale population trials confirm that these routine screenings reliably catch localized disease and reduce mortality.

Currently, major medical societies—including the American Cancer Society and the American Gastroenterological Association—do not endorse MCED tests as standalone screening tools or as replacements for standard preventive care [3].

5. False Positives, Predictive Value, and Diagnostic Cascades

Relying on multi-cancer blood panels in asymptomatic individuals introduces two major clinical risks:

The Low Positive Predictive Value (PPV)

Although the Galleri test boasts a high analytical specificity of roughly 99.5%, applying it across a broad population yields a Positive Predictive Value of approximately 38% to 44% in prospective studies like PATHFINDER [1, 2].

This means that for every 10 asymptomatic patients who receive a flagged positive result, 5 to 6 of them do not have cancer [2]. Many false-positive signals arise from benign clonal expansions of blood cells (such as clonal hematopoiesis or monoclonal B-cell lymphocytosis) rather than solid tumors.

The Diagnostic Cascade

When an asymptomatic patient receives an abnormal cancer signal, it triggers an extensive and urgent clinical workup:

• Full-body PET-CT scans, abdominal MRIs, and endoscopic procedures.

• Significant medical radiation exposure and out-of-pocket diagnostic costs.

• Immense psychological distress and anxiety while searching for a tumor that may not exist.

The Risk of False Reassurance

Conversely, a "negative" MCED result can create a false sense of security. Because the assay misses the majority of Stage I malignancies, a patient who uses a normal blood test as a reason to delay their routine colonoscopy or mammogram is inadvertently increasing their risk of late-stage disease [3].

Multi-cancer early detection blood tests represent a sophisticated development in genomic profiling, but they remain investigational screening tools [1, 4].

If an individual chooses to pursue an MCED test like Galleri, it must be approached strictly as an adjunctive, exploratory tool—never as a substitute for proven screening. It may help identify a subset of aggressive malignancies (such as pancreatic, ovarian, or esophageal cancers) that currently lack standard screening protocols, but its impact on long-term survival remains unproven.

Effective cancer prevention remains grounded in validated fundamentals: tobacco avoidance, metabolic optimization, limiting alcohol, maintaining physical fitness, and staying strictly up to date on guideline-recommended screenings.

To simulate the results of Galleri testing and/or whole body MRI for your age, sex, and family history, use our free Cancer Screening Engine.

Track your broader cardiovascular, metabolic, and physical health markers with the free Healthspan Engine.

Have questions about evaluating new screening tests, interpreting complex lab results, or personalizing your preventive health roadmap? Ask our physicians directly through our Weekly Healthspan Q&A—we answer reader-submitted questions every week in our newsletter.

(Disclosure: The Cancer Screening Engine, Healthspan Engine, and Weekly Q&A are free educational resources provided by delaeMD.)

References

1. Klein EA, Richards D, Cohn A, et al. Clinical Validation of a Targeted Methylation-Based Multi-Cancer Early Detection Test Using an Independent Validation Set. Annals of Oncology. 2021;32(9):1167-1177.

2. Matrana M, Shukla V, Kingsbury D, et al. Real-World Data and Clinical Experience From Over 100,000 Multi-Cancer Early Detection Tests. Nature Communications. 2025;16(1):9625.

3. Hoffman RM, Wolf AMD, Raoof S, et al. Multicancer Early Detection Testing: Guidance for Primary Care Discussions With Patients. Cancer. 2025;131(7):e35823.

4. Rubin R. These Blood Tests May Detect Dozens of Cancers, but Will They Save Lives?. JAMA. 2026;10.1001/jama.2026.4742.